# XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC

> **NCT06742411** · PHASE1,PHASE2 · RECRUITING · sponsor: **West China Hospital** · enrollment: 57 (estimated)

## Conditions studied

- Gastric (Stomach) Cancer

## Interventions

- **DRUG:** XELOX+Sintilimab+HBOT

## Key facts

- **NCT ID:** NCT06742411
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-31
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 57 (ESTIMATED)
- **Last updated:** 2025-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06742411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06742411, "XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT06742411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*